期刊文献+

老年患者择期冠状动脉介入治疗中低剂量比伐卢定安全性观察 被引量:7

The use of low-dose bivalirudin in elderly patients receiving elective percutaneous coronary intervention:observation of its safety
下载PDF
导出
摘要 目的探讨老年患者择期经皮冠状动脉介入治疗(PCI)中应用低剂量比伐卢定的安全性。方法连续选取年龄>65岁冠心病患者162例,随机分为标准剂量组(n=80)和低剂量组(n=82)。PCI术前两组患者接受静脉推注负荷剂量比伐卢定0.75 mg/kg,术中标准剂量组以1.75 mg·kg^(-1)·h^(-1)加术后0.2 mg·kg^(-1)·h^(-1)剂量持续给药2 h,低剂量组以1.5 mg·kg^(-1)·h^(-1)加术后0.15 mg·kg^(-1)·h^(-1)剂量持续给药2 h。对比分析两组患者给药后5 min、30 min、手术终止时、术后1 h活化凝血时间(ACT)值以及术后1个月内出血事件、心肌梗死、靶血管重建、支架内血栓、不明原因卒中发生率。结果低剂量组给药后30 min、手术终止时、术后1 h ACT值与标准剂量组相比均明显降低,分别为(331.2±53.5)s对(383.5±74.7)s、(324.9±47.6)s对(371.3±65.4)s、(289.6±34.9)s对(314.8±43.1)s,P值均<0.001。两组患者术后1个月内心肌梗死、一般出血事件发生率比较,差异均无统计学意义(P>0.05),未发生大出血、靶血管重建、支架内血栓和不明原因卒中事件。结论老年冠心病患者择期PCI术中应用低剂量比伐卢定抗凝。 Objective To evaluate the safety of using of low-dose bivalirudin in elderly patients who receive elective percutaneous coronary intervention (PCI) for coronary artery disease (CAD). Methods A total of 162 continuously encountered patients (〉65 years) with CAD were included in this study. The patients were randomly divided into standard dose group (group B, n=80) and low-dose group (group A, n=82). Before PCI, an intravenous bolus injection of bivalirudin (0.75 mg/kg) was performed in all patients of both groups. For patients of group B, intraoperative use of 1.75 mg·kg^-1·h^-1 bivalirudin and postoperative use of 0.2 mg·kg^-1·h^-1 bivalirudin lasting for two hours were employed; while for patients of group A, intraoperative use of 1.5 mg·kg^-1·h^-1 bivalirudin and postoperative use of 0.15 mg·kg^-1·h^-1 bivalirudin lasting for two hours were adopted. The activated clotting time (ACT) was determined at 5 min, 30 min, the end-point of operation and 60 min after operation separately. The complications occurred within one month after PCI, such as bleeding event, myocardial infarction, target vessel revascularization, stent thrombosis and stroke of unknown origin, were recorded. The results were compared between the two groups. Results The ATC values determined at 30 min, the end-point of operation and 60 min after operation in the group A were significantly lower than those in the group B, the results being (331.2±53.5) s vs. (383.5±74.7) s, (324.9±47.6) s vs. (371.3±65.4) s and (289.6±34.9) s vs. (314.8±43.1) s, respectively (P〈0.001). No significant differences in the incidences of myocardial infarction and general bleeding event within one month after PCI existed between the two groups (P〉0.05), and no massive hemorrhage, target vessel revascularization, stent thrombosis and stroke of unknown origin occurred in both groups. Conclusion In treating elderly CAD patients with selective PCI, the intraoperative use of low-dose bivalirudin is safe and effective.
出处 《介入放射学杂志》 CSCD 北大核心 2016年第3期250-253,共4页 Journal of Interventional Radiology
关键词 冠状动脉疾病 老年人 经皮冠状动脉介入治疗 比伐卢定 coronary artery disease the aged percutaneous coronary intervention bivalirudin
  • 相关文献

参考文献16

  • 1Levine GN,Bates ER,Blankenship JC,et al.2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J].Circulation,2011,124:e574-e651.
  • 2Stone GW,Ware JH,Bertrand ME,et al.Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management:one-year results from the ACUITY trial[J].JAMA,2007,298:2497-2506.
  • 3Kastrati A,Mehilli J,Neumann FJ,et al.Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment:the ISAR-REACT 2 randomized trial[J].JAMA,2006,295:1531-1538.
  • 4Schulz S,Mehilli J,Ndrepepa G,et al.Bivalirudin vs.unfractio-nated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris:1-year results of the ISAR-REACT 3 trial[J].Eur Heart J,2010,31:582-587.
  • 5Ashby DT,Dangas G,Aymong EA,et al.Relation between the degree of procedural anticoagulation and complications after coronary stent implantation[J].Am J Cardiol,2003,92:319-322.
  • 6Ndrepepa G,Berger PB,Mehilli J,et al.Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions:appropriateness of including bleeding as a component of a quadruple end point[J].J Am Coll Cardiol,2008,51:690-697.
  • 7Lincoff AM,Kleiman NS,Kereiakes DJ,et al.Long-term efficacy of bivalirudin and provisional glycoprotein Ⅱb/Ⅲa blockade vs heparin and planned glycoprotein Ⅱb/Ⅲa blockade during percutaneous coronary revascularization:REPLACE-2 randomized trial[J].JAMA,2004,292:696-703.
  • 8Kastrati A,Neumann FJ,Mehilli J,et al.Bivalirudin versus unfractionated heparin during percutaneous coronary intervention[J].N Engl J Med,2008,359:688-696.
  • 9Cutlip DE,Windecker S,Mehran R,et al.Clinical end points in coronary stent trials:a case for standardized definitions[J].Circulation,2007,115:2344-2351.
  • 10王珏,施万印.抗凝、抗血小板及溶栓药物的合理应用[J].介入放射学杂志,2011,20(1):76-81. 被引量:13

二级参考文献48

  • 1周平,李法琦.常用抗血小板和抗凝药物在心脑血管疾病中的应用[J].心血管病学进展,2004,25(5):338-341. 被引量:10
  • 2Schulz S,Mehilli J,Ndrepepa G,et al.Bivalirudin vs.unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris:1-year results of the ISAR-REACT 3 trial.Eur Heart J,2010,31(5):582-587.
  • 3Lincoff AM,Bittl JA,Harrington RA,et al.Bivalirudin and provisional glycoprotein Ⅱb/Ⅲa blockade compared with heparin and planned glycoprotein Ⅱb/Ⅲa blockade during percutaneous coronary intervention:REPLACE-2 randomized tria.JAMA,2003,289(7):853-863.
  • 4Kim LK,Wong SC,Minutello RM,et al.Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.J Invasive Cardiol,2010,22(3):94-100.
  • 5D(i)ez JG,Wilson JM.Practical Strategies for the Management of Anticoagulation Therapy:Unsolved Issues in the Cardiac Catheterization Laboratory.Cardiovasc Drugs Ther,2010,24(2):161-174.
  • 6Shammas NW,Shammas GA,Jerin M,et al.In-hospital safety and effectiveness of bivalirudin in percutaneous peripheral interventions:data from a real-world registry.J Endovasc Ther,2010,17(1):31-36.
  • 7Delhaye C,Maluenda G,Wakabayashi K,et al.Safety and in-hospital outcomes of bivalirudin use in dialysis patients undergoing percutaneous coronary intervention.Am J Cardiol,2010,105(3):297-301.
  • 8Doll JA,Nikolsky E,Stone GW,et al.Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy:pooled analysis from REPLACE-2,ACUITY,and HORIZONS-AMI trials.J Interv Cardiol,2009,22(5):453-459.
  • 9Rassen JA,Mittleman MA,Glynn RJ,et al.Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention.Eur Heart J,2010,31(5):561-572.
  • 10Lincoff AM,Bittl JA,Harrington PA,et al.Bivalirudin and provisional glycoprotein Ⅱb/Ⅲa blockade compared with heparin and planned glycoprotein Ⅱb/Ⅲa blockade during percutaneous coronary intervention:REPLACE-2 randomized trial.JAMA,2003,289(7):853-863.

共引文献44

同被引文献45

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部